UY27844A1 - Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva. - Google Patents

Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva.

Info

Publication number
UY27844A1
UY27844A1 UY27844A UY27844A UY27844A1 UY 27844 A1 UY27844 A1 UY 27844A1 UY 27844 A UY27844 A UY 27844A UY 27844 A UY27844 A UY 27844A UY 27844 A1 UY27844 A1 UY 27844A1
Authority
UY
Uruguay
Prior art keywords
substituted
preparations
stratriens
alfa
strategies
Prior art date
Application number
UY27844A
Other languages
English (en)
Spanish (es)
Inventor
Dirk Kosemund
Gerd Muller
Alexander Hillisch
Peter Muhn
Karl-Heinrich Fritzemeier
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY27844A1 publication Critical patent/UY27844A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0055Estrane derivatives not substituted in position 17
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0066Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UY27844A 2002-06-11 2003-06-11 Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva. UY27844A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10226326A DE10226326A1 (de) 2002-06-11 2002-06-11 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene

Publications (1)

Publication Number Publication Date
UY27844A1 true UY27844A1 (es) 2003-12-31

Family

ID=29723144

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27844A UY27844A1 (es) 2002-06-11 2003-06-11 Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva.

Country Status (28)

Country Link
EP (1) EP1517914B1 (https=)
JP (1) JP4615998B2 (https=)
KR (1) KR101006612B1 (https=)
CN (1) CN1293090C (https=)
AR (1) AR040188A1 (https=)
AT (1) ATE303397T1 (https=)
AU (1) AU2003242683B9 (https=)
BR (1) BR0312140A (https=)
CA (1) CA2486495C (https=)
CR (1) CR10289A (https=)
CU (1) CU23414B7 (https=)
DE (2) DE10226326A1 (https=)
DK (1) DK1517914T3 (https=)
EA (1) EA008442B1 (https=)
EC (1) ECSP055530A (https=)
ES (1) ES2248770T3 (https=)
HR (1) HRP20050009B1 (https=)
IL (1) IL165321A (https=)
MX (1) MXPA04012491A (https=)
NO (1) NO329563B1 (https=)
PE (1) PE20040613A1 (https=)
PL (1) PL209910B1 (https=)
RS (1) RS50878B (https=)
TW (1) TWI286140B (https=)
UA (1) UA78062C2 (https=)
UY (1) UY27844A1 (https=)
WO (1) WO2003104253A2 (https=)
ZA (1) ZA200500217B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE602004014020D1 (de) * 2003-11-26 2008-07-03 Bayer Schering Pharma Ag Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol und 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057224A1 (de) 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP2252261A2 (en) * 2008-02-13 2010-11-24 Bayer Schering Pharma Aktiengesellschaft Drug delivery system with stabilising effect
EP2143432A1 (en) 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
WO2010057594A1 (en) * 2008-11-21 2010-05-27 Bayer Schering Pharma Aktiengesellschaft Drug delivery system
US10821152B2 (en) 2014-08-26 2020-11-03 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
US11787835B2 (en) * 2018-09-07 2023-10-17 Trustees Of Dartmouth College C19 scaffolds and steroids and methods of use and manufacture thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2336432A1 (de) * 1973-07-13 1975-01-30 Schering Ag 3.17.18-trihydroxy-1.3.5(10)-oestratriene
US6154158A (en) * 1998-06-30 2000-11-28 Qualcomm Incorporated Digital-to-analog converter D.C. offset correction comparing converter input and output signals
DE19906159A1 (de) * 1999-02-09 2000-08-10 Schering Ag 16-Hydroxyestratriene als selektiv wirksame Estrogene
PT1226155E (pt) * 1999-11-02 2007-07-26 Bayer Schering Pharma Ag 18-nor-esteróides como estrogénios selectivamente activos
ATE302790T1 (de) * 2000-04-12 2005-09-15 Schering Ag 8beta-substituierte-11beta-pentyl-und 11beta- hexyl-estra-1,3,5(10)-trienderivate

Also Published As

Publication number Publication date
HRP20050009A2 (en) 2005-04-30
JP2005533053A (ja) 2005-11-04
CN1659181A (zh) 2005-08-24
CR10289A (es) 2008-11-26
RS50878B (sr) 2010-08-31
EP1517914A2 (de) 2005-03-30
NO20050127D0 (no) 2005-01-10
TW200407331A (en) 2004-05-16
EA200401544A1 (ru) 2005-06-30
PE20040613A1 (es) 2004-12-01
CA2486495A1 (en) 2003-12-18
DE50301116D1 (de) 2005-10-06
CN1293090C (zh) 2007-01-03
DK1517914T3 (da) 2006-01-16
EA008442B1 (ru) 2007-06-29
BR0312140A (pt) 2005-04-05
UA78062C2 (en) 2007-02-15
ATE303397T1 (de) 2005-09-15
PL209910B1 (pl) 2011-11-30
AR040188A1 (es) 2005-03-16
WO2003104253A2 (de) 2003-12-18
ECSP055530A (es) 2005-03-10
CA2486495C (en) 2011-04-19
CU23414B7 (es) 2009-09-08
NO20050127L (no) 2005-03-11
RS107004A (sr) 2006-10-27
ES2248770T3 (es) 2006-03-16
AU2003242683B2 (en) 2009-07-02
KR101006612B1 (ko) 2011-01-10
KR20050009745A (ko) 2005-01-25
NO329563B1 (no) 2010-11-15
ZA200500217B (en) 2006-03-29
JP4615998B2 (ja) 2011-01-19
DE10226326A1 (de) 2004-01-15
AU2003242683A1 (en) 2003-12-22
HRP20050009B1 (hr) 2013-07-31
EP1517914B1 (de) 2005-08-31
HK1081203A1 (en) 2006-05-12
AU2003242683B9 (en) 2009-08-27
IL165321A (en) 2009-08-03
PL373090A1 (en) 2005-08-08
MXPA04012491A (es) 2005-06-08
WO2003104253A3 (de) 2004-09-16
TWI286140B (en) 2007-09-01

Similar Documents

Publication Publication Date Title
ATE323473T1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
HN2000000267A (es) Oxazolidinonas substituidas y su uso
BR0107869A (pt) Composições farmacêuticas eletrogiradas
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
AR048017A1 (es) Composicion y metodo para aumentar la biodisponibilidad
PA8553101A1 (es) Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
BR0109150A (pt) Método para administração de um anestésico local a um indivìduo em necessidade de um efeito anestésico local, emplastro, composição, e, recipiente
AR069830A1 (es) Factor viii y factor de von willebrand recombinantes modificados y metodos de uso de los mismos
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
CL2003002769A1 (es) Compuestos derivados de carboxamida de tiazolilpirrol; procedimiento para su preparacion; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion de receptores canabinoid
CR10289A (es) "estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional)
TW200602031A (en) Antiinflammatory and pain-relieving agent for external, use
MX2007009032A (es) Formulacion para inyeccion de butanos catecolicos incluyendo compuestos ndga en animales.
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
PA8532001A1 (es) Bifenilcarboxamidas utiles como agentes reductores de lipidos
BR0318343A (pt) composição tópica para administração transdérmica
PA8571401A1 (es) Imidazolinilmetil aralquilsulfonamidas
PT2190431E (pt) Composições compreendendo um agonista do recetor dos glucocorticoides dissociados para tratamento ou controlo de inflamação do segmento anterior
BR0308795A (pt) Amidas do ácido sulfamico
PE20011260A1 (es) Derivados de sulfonamida
UY26665A1 (es) Estratrienos sustituidos como estrógenos selectivamente activos
CU20100008A7 (es) Estratrienos 8-beta sustituidos como estrógenos de acción selectiva
PE20050207A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros referida a enfermedades dependientes de hormonas
BR0009194A (pt) Composição do resorcinol

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150427